Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q2 2025 · 10-Q
Revenue$1.46M$1.46M— vs Q2 2024 Net Income-$25.77M-$25.77MN/M vs Q2 2024 EPS Diluted-$2.74-$2.74N/M vs Q2 2024 Operating Income-$27,202,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$19,368,000N/M Margins · derivedOperating margin-1863.2%
Net margin-1765.1%
ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d after period end